High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0584
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma ; day:24 ; month:2 ; year:2021 ; pages:1-13
Annals of hematology ; (24.2.2021), 1-13

Urheber
Swoboda, Ryszard
Giebel, Sebastian
Knopińska-Posłuszny, Wanda
Chmielowska, Ewa
Drozd-Sokołowska, Joanna
Paszkiewicz-Kozik, Ewa
Kulikowski, Waldemar
Taszner, Michał
Mendrek, Włodzimierz
Najda, Jacek
Czerw, Tomasz
Olszewska-Szopa, Magdalena
Czyż, Anna
Giza, Agnieszka
Spychałowicz, Wojciech
Subocz, Edyta
Szwedyk, Paweł
Krzywon, Aleksandra
Wilk, Agata
Zaucha, Jan Maciej
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00277-021-04448-5
URN
urn:nbn:de:101:1-2021050919221545723192
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:00 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Swoboda, Ryszard
  • Giebel, Sebastian
  • Knopińska-Posłuszny, Wanda
  • Chmielowska, Ewa
  • Drozd-Sokołowska, Joanna
  • Paszkiewicz-Kozik, Ewa
  • Kulikowski, Waldemar
  • Taszner, Michał
  • Mendrek, Włodzimierz
  • Najda, Jacek
  • Czerw, Tomasz
  • Olszewska-Szopa, Magdalena
  • Czyż, Anna
  • Giza, Agnieszka
  • Spychałowicz, Wojciech
  • Subocz, Edyta
  • Szwedyk, Paweł
  • Krzywon, Aleksandra
  • Wilk, Agata
  • Zaucha, Jan Maciej
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Fluorodeoxyglucose-Positron Emission Tomography in Relapsed/Refractory Hodgkin Lymphoma: A Practical Approach

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan

Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Analysis of Relapsed/Refractory Hodgkin Lymphoma Treated with Autologous Transplantation: A Single-Center Experience

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

Verbundene Objekte